Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Stopped Dosing completed in all cohorts. Planning underway for potential additional patient cohorts.
Conditions
- Acute Myelogenous Leukemia
- Myelodysplastic Syndrome
Interventions
- DRUG: Emavusertib
- DRUG: Venetoclax
- DRUG: Emavusertib
Sponsor
Curis, Inc.